Related Experiment Videos
Beta-blockers in heart failure: is more better?
Lawrence Baruch1, Prabhakara Kunamneni
1Bronx VA Medical Center, 130 West Kingsbridge Road, Bronx, NY 10468, USA. baruchlarry@att.net
Current Heart Failure Reports
|July 23, 2005
Summary
Beta-blockers are underused in heart failure treatment. This review explores if higher doses of beta-blockers improve patient outcomes, addressing the question "Is more better?" for heart failure management.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Sympathetic nervous system and renin-angiotensin-aldosterone system modulators reduce heart failure morbidity and mortality.
- These therapies are underused, with suboptimal doses frequently prescribed in clinical practice.
Purpose of the Study:
- To investigate the relationship between beta-blocker dosage and clinical outcomes in heart failure.
- To address whether higher doses of beta-blockers are more effective in reducing morbidity and mortality.
Main Methods:
- Review of clinical trials involving neurohormonal modulators across the cardiovascular continuum.
- Analysis of studies to infer the dose-response relationship for beta-blockers.
Main Results:
- Limited direct dose-comparison trials for beta-blockers exist.
- Broader evidence from neurohormonal modulator trials is used to address the dose-efficacy question.
Conclusions:
- The optimal dosing strategy for beta-blockers in heart failure requires further investigation.
- Evidence suggests a potential benefit of higher doses, but more research is needed to confirm "Is more better?"